6-Methoxypurine arabinoside (ara-M) exhibits potent activity against varicella-zoster virus (VZV) as a result of ara-M's anabolism to the triphosphate of adenine arabinoside (ara-ATP) in VZV-infected cells. The adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) enhanced the formation of ara-ATP by inhibiting ara-M demethoxylation. In contrast, deoxycoformycin and coformycin, inhibitors of both adenosine deaminase and AMP deaminase, blocked the formation of ara-ATP and reversed the anti-VZV activity of ara-M. These results indicate that after the initial phosphorylation of ara-M by the VZV-coded thymidine kinase, the monophosphate is demethoxylated by AMP deaminase to form ara-IMP, which is converted to ara-ATP by the sequential actions of the cellular adenylosuccinate synthetase, adenylosuccinate lyase, and nucleotide kinases.
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6-Methoxypurine arabinoside (ara-M) is an efficient substrate for the varicella-zoster virus (VZV)-coded thymidine kinase but is not detectably phosphorylated by cellular nucleoside kinases (4) . Studies with radiolabeled ara-M in VZV-infected cells revealed the accumulation of a triphosphate which was characterized not as ara-M triphosphate (ara-MTP) but rather as the triphosphate of adenine arabinoside (ara-ATP) (5) . In contrast, ara-ATP was not detectable in uninfected cells exposed to ara-M. To characterize the intracellular pathway involved in the conversion of ara-M to ara-ATP, cellular metabolism studies were performed in the presence and absence of the specific enzyme inhibitors erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), deoxycoformycin, coformycin, and hadacidin. Parallel studies were conducted with ara-A for comparison.
Ara-M and EHNA were obtained as described in an earlier paper (4) . [G-3H]ara-M (16 Ci/mmol) and [2,8-3H] ara-A (40 Ci/mmol) were obtained as previously described (5) . [8-14C] ara-M (49 Ci/mol) was synthesized in our laboratories (6) . The monophosphate of [8-14C] ara-M was synthesized in these laboratories by Wayne Miller, who used published procedures (12, 22) . Deoxycoformycin was purchased from Sigma Chemical Co., St. Louis, Mo., and coformycin was obtained from Calbiochem, La Jolla, Calif. Hadacidin was a gift from Buddy Ullman (University of Oregon, Portland).
Cellular metabolism studies. Human foreskin fibroblasts (HFF) were coseeded into flasks with VZV Oka-infected cells at a ratio of infected (80% cytopathic effect) to uninfected cells of 1:5. Infections were allowed to establish for 12 h (5) before radiolabeled compounds (100 ,uM; 10 to 15 ,uCi/ml) were added in the presence or absence of specific inhibitors. After addition of the compounds, the incubations were continued for 24 h. All experiments were carried out in duplicate, and experimental samples were pooled at harvest * Corresponding author. in order to provide sufficient radioactivity for quantitation. Cells were harvested and extracted with 60% methanol, and cellular anabolites were analyzed by anion-exchange highperformance liquid chromatography (5) .
Preparation of cell extracts for measurement of AMP deaminase activity. Uninfected and VZV-infected HFF were dislodged from culture flasks and washed three times in cold phosphate-buffered saline with centrifugation at 200 x g for 10 min. The resulting cell pellet was suspended in 10 volumes of a hypotonic buffer used to extract cells (7); deoxythymidine was omitted, and 1 mM ATP was added. The supernatant was brought to 40 mM KCl by the addition of 4 M KCl and then made 10% with respect to glycerol. Aliquots of this cytosolic fraction (7) The aliquots were immediately mixed with 2 RI of Escherichia coli alkaline phosphatase (1 U/pA) containing 140 mM diethanolamine (pH 9.8), 1 mM MgCI2, and 0.1 mM ZnCl2 and incubated at 30°C for 30 min. The sample was then spotted onto a silica gel thin-layer chromatography plate which had been prespotted with 10 nmol each of adenosine, inosine, and hypoxanthine. The plate was developed in acetonitrile-H20-NH4OH (85:10:5). The spot corresponding to adenosine (Rf = 0.33) and the combined area corresponding to inosine (Rf = 0.13) and hypoxanthine (Rf = 0.22) were cut out, and the radioactivity was quantitated by liquid scintillation. When ara-MMP served as substrate, the spot corresponding to ara-M (R = 0.43) and the combined area corresponding to hypoxanthine arabinoside (ara-H) (Rf = ANTIMICROB. AGENTS CHEMOTHER. 0.13) and hypoxanthine (Rf = 0.22) were cut out and the radioactivity was quantitated by liquid scintillation.
For measurement of potentially interfering levels of AMP phosphatase (or ara-MMP phosphatase) in the reactions described above, aliquots were spotted directly onto a polyethyleneimine-cellulose thin-layer chromatography plate which had been prespotted with 5 nmol of adenosine (or ara-M) and AMP (or ara-MMP). The plate was developed in H20. The spots corresponding to AMP or ara-MMP (Rf = 0.0), adenosine (Rf = 0.59), and ara-M (Rf = 0.81) were cut out, and the radioactivity was quantitated by liquid scintillation.
Ara-M inhibition of VZV replication was not affected by EHNA, but it was blocked by deoxycoformycin and coformycin in HFF (Table 1) . Similar results were obtained with VZV-infected MRC-5 cells (data not shown).
More ara-ATP was derived from ara-M in VZV-infected HFF in the presence of EHNA, an inhibitor of adenosine deaminase (16) but not AMP deaminase (1), than in its Methods. I Differences in the extent of ara-M phosphorylation may reflect differences in the degree of VZV thymidine kinase induction. absence (Table 2) . Similar results were obtained in cells incubated with ara-A, although the magnitude of the increase of ara-ATP was greater with ara-A than with ara-M.
In contrast to the effects with EHNA, the addition of deoxycoformycin to VZV-infected HFF exposed to ara-M resulted in a dramatic decline in ara-A phosphates, particularly ara-ATP, and a marked elevation in ara-MMP. The effect was even more dramatic in the presence of coformycin (Table 2 ). This correlates with the greater effect of coformycin on virus sensitivity (Table 1 ) and the inhibition of AMP deaminase (1) . Since both deoxycoformycin and coformycin inhibit AMP deaminase in addition to adenosine deaminase (1, 2, 9), these results suggested that ara-IMP, derived from demethoxylation of ara-MMP, was an intermediate in the formation of ara-ATP. The changes in levels of ara-IMP in the presence and absence of these inhibitors (Table 2) are also consistent with this view.
VZV-infected HFF treated with ara-A and deoxycoformycin exhibited an intracellular ara-ATP concentration which was six times higher than that observed in the absence of deoxycoformycin. With coformycin, there was a sevenfold increase in ara-ATP formation (Table 2 ). These findings indicate that, as with cells treated with EHNA, it is the protective effect afforded to ara-A by adenosine deaminase inhibition that causes increases in the ara-ATP pool. In the case of ara-A, inhibition of AMP deaminase does not play a role.
Inclusion of hadacidin, an inhibitor of adenylosuccinate synthetase (17, 18) , caused a marked decrease in the amount of ara-ATP derived from ara-M (Table 2 ). These data suggest that adenylosuccinate synthetase is involved in the conversion of ara-M to ara-ATP. In parallel experiments, the ara-ATP pool derived from ara-A was unaffected by hadacidin, suggesting that adenylosuccinate synthetase was not involved in the conversion of ara-A to ara-ATP.
In light of the apparent key role of AMP deaminase in the pathway from ara-M to ara-ATP, the enzyme was purified from human erythrocytes according to the procedure of Nathans et al. (15) , and its ability to demethoxylate ara-MMP was investigated. The purified enzyme catalyzed the demethoxylation of ara-MMP with a Km of 0.24 mM and a maximal velocity of 0.021% that of AMP (Km = 0.5 mM).
The possibility of VZV-dependent induction of AMP deaminase was also investigated. In extracts of uninfected and VZV-infected HFF, the rates of AMP deamination (32.9 ± 2.2 and 32.1 + 1.9 nmol/min/mg, respectively, n = 3) and ara-MMP demethoxylation (0.03 and 0.025 nmol/min/mg, respectively) were virtually identical, indicating that AMP deaminase activity was not increased by viral infection. If these velocity measurements are used, the calculated cellular potential for demethoxylation of ara-M monophosphate exceeds, by at least 1 order of magnitude, that required to account for the ara-MMP-derived metabolites reported on in Table 2 .
The data previously reported (4, 5) together with that presented here are consistent with a pathway which involves the initial phosphorylation of ara-M to ara-MMP by VZVcoded thymidine kinase followed by demethoxylation of the ara-MMP to ara-IMP by the cellular AMP deaminase (Fig.  1) pathway leading from ara-M to ara-ATP in VZV-infected cells. These data were supported by demonstrating that the human enzyme was capable of demethoxylating ara-MMP to ara-IMP (see above). The further conversion of ara-IMP to ara-AMP has been shown to be catalyzed by cellular adenylosuccinate synthetase (21) and adenylosuccinate lyase (20) . The involvement of this pathway was demonstrated by blocking the formation of ara-ATP with hadacidin, an inhibitor of adenylosuccinate synthetase (Table 2) . This pathway was also proposed recently (3) for the conversion of dideoxyinosine monophosphate to dideoxyadenosine monophosphate. The lack of a significant elevation in ara-IMP levels in the presence of hadacidin is probably a result of its dephosphorylation to ara-H, as has been reported for IMP (8, 11, 14) . Further phosphorylation of ara-AMP by host nucleotide kinases would result in the formation of ara-ATP.
A second possible pathway for the conversion of ara-M to ara-IMP involves the adenosine deaminase-catalyzed demethoxylation of ara-M to ara-H (19) followed by phosphorylation of ara-H to ara-IMP by deoxycytidine kinase (13) . However, the observed elevation in ara-ATP levels after adenosine deaminase is blocked with EHNA (Table 2) indicates that this metabolic pathway is not the major one. Furthermore, ara-M is a much more potent anti-VZV agent than is ara-H (4), a finding that would be difficult to explain if ara-H served as an intermediate in the pathway to ara-ATP. In addition, incubation of [3H]ara-H with VZV-infected HFF resulted in virtually no anabolism to ara-ATP (5) . In a second series of studies, essentially the same results were obtained with VZV-infected MRC-5 cells (data not shown).
In light of the available data, it appears most likely that the major pathway for the conversion of ara-M to ara-ATP in VZV-infected cells is that outlined in Fig. 1 , and this pathway appears to be different from that involved in the anabolism of ara-A to ara-ATP (10) .
